Sharon Golden Myers
Psychiatric/Mental Health · Hickory, NCNPI 1346331568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,640 and has fallen 50.7% since, to $1,301 in 2025. Among psychiatric/mental health clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 305 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$937
- Alkermes, Inc.$842
- Johnson & Johnson$668
- USWM, LLC$506
- plus $2K from 20 others
What the payments were for
- Food & beverage$7,28793%
- Education$1412%
- Gifts$4095%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 60 | $1,302 |
| AbbVie | 48 | $1,154 |
| Otsuka America Pharmaceutical, Inc. | 28 | $937 |
| Alkermes, Inc. | 31 | $842 |
| Johnson & Johnson | 24 | $668 |
| USWM, LLC | 7 | $506 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $373 |
| Lilly USA, LLC | 12 | $292 |
| Bayer | 15 | $252 |
| Lundbeck LLC | 12 | $236 |
| Neurocrine Biosciences, Inc. | 11 | $202 |
| Novo Nordisk | 6 | $164 |
| Indivior Inc. | 9 | $160 |
| Axsome Therapeutics, Inc. | 2 | $149 |
| Sunovion Pharmaceuticals Inc. | 8 | $132 |
| Vanda Pharmaceuticals Inc. | 5 | $124 |
| E.r. Squibb & Sons, L.L.C. | 2 | $81 |
| Abbott | 4 | $67 |
| Astellas Pharma US Inc | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $30 |
| Corium, LLC | 1 | $21 |
| Pfizer | 1 | $20 |
| Biogen | 1 | $17 |
| Novartis | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$518
- LUCEMYRA$409
- VRAYLAR$283
- INVEGA SUSTENNA$250
- REXULTI$235
- CAPLYTA$130
- AUSTEDO$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Auvelity$124
- Austedo XR$114
How this compares
$7,838 in reported general payments places this provider in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 24 | $80,127 |
| RexultiBrexpiprazole | 12 | $20,353 |
| TrintellixVortioxetine Hydrobromide | 11 | $7,434 |
| Clozapine | 19 | $3,579 |
| Asenapine Maleate | 11 | $2,472 |
| Paliperidone ErPaliperidone | 11 | $1,617 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,604 |
| Bupropion XlBupropion Hcl | 14 | $750 |
| Trazodone Hcl | 45 | $415 |
| Duloxetine Hcl | 22 | $308 |
| Gabapentin | 11 | $270 |
| Olanzapine | 16 | $215 |
| Fluoxetine Hcl | 15 | $210 |
| Mirtazapine | 15 | $162 |
| Sertraline Hcl | 17 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $668 | $80,12724 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $937 | $20,35312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $7,43411 claims |
| Lilly USA, LLCOlanzapine | $292 | $21516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Hickory
- Francis PenlandHickory$17K
- Kenneth LevesqueHickory$10K
- Alicia BuckHickory$9K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Hannah NealeyFuquay Varina$75K
- Jessica StoneRocky Mount$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.